ResMed Inc. (RMD) Stock Forecast
RMD analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.70 / 5 from 20 analysts
- Price target
- $251.99 average of analyst targets
- Upside to target
- +5.4% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $2.70
- 52-week range
- $182.82 – $275.96
RMD analyst ratings
20 analystsNumber of analysts at each rating.
RMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.67 | $2.62 | $2.76 | $2.55 | +4.6% | 13 |
| Next quarter (Dec '26) | $3.03 | $2.89 | $3.11 | $2.81 | +7.8% | 13 |
| Current fiscal year (FY2027) | $12.08 | $11.82 | $12.17 | $11.17 | +8.2% | 20 |
| Next fiscal year (FY2028) | $13.23 | $12.74 | $13.70 | $12.08 | +9.5% | 20 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.39B | $1.36B | $1.42B | +4.1% | 14 |
| Next quarter (Dec '26) | $1.45B | $1.44B | $1.46B | +1.9% | 13 |
| Current fiscal year (FY2027) | $5.80B | $5.74B | $5.85B | +2.6% | 20 |
| Next fiscal year (FY2028) | $6.20B | $6.09B | $6.58B | +6.9% | 19 |
RMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RMD revenue: reported and forecast
RMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.83 | $2.69 | $2.68 | $2.67 | $2.67 | −5.8% | 0 up · 1 down |
| Next quarter (Dec '26) | $3.04 | $3.04 | $3.03 | $3.03 | $3.03 | −0.3% | 0 up · 1 down |
| Current fiscal year (FY2027) | $12.06 | $12.10 | $12.08 | $12.09 | $12.08 | +0.2% | 0 up · 2 down |
| Next fiscal year (FY2028) | $13.22 | $13.24 | $13.23 | $13.23 | $13.23 | +0.0% | 3 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RMD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RMD beat in 12 of 12.
What analysts expect from RMD
20 analysts cover ResMed; their consensus rating is buy (3.70 on a 1–5 scale, where 5 is a strong buy). The average price target is $251.99, 5.4% above the latest close of $238.97. Analysts expect earnings of $12.08 per share for FY2027, +8.2% from a year earlier. For FY2028 the average estimate is $13.23 per share on revenue of $6.2 billion. ResMed beat the EPS estimate in 12 of the last 12 quarters.
Related: RMD income statement, RMD key metrics, RMD chart. See the RMD stock overview for the latest quote and news.
RMD forecast FAQ
What is ResMed's price target?
The average analyst price target for ResMed is $251.99, 5.4% above the latest close of $238.97.
Is ResMed a buy, hold or sell?
Of 20 analysts covering ResMed, 7 rate it a strong buy, 2 a buy, 10 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ResMed's EPS forecast?
Analysts forecast $12.08 per share for FY2027 (range $11.82 to $12.17); for FY2028 the estimate is $13.23.
What is ResMed's revenue forecast?
The average revenue estimate for FY2027 is $5.8 billion, growth of 2.6%; for FY2028 it is $6.2 billion.
When does ResMed report earnings?
ResMed is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $2.70.
Does ResMed usually beat earnings estimates?
ResMed reported EPS at or above the analyst estimate in 12 of the last 12 quarters.